Renaissance Technologies
LENZ

Renaissance Technologies’s LENZ Therapeutics LENZ Stock Holding History

Renaissance Technologies’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-25,366
Closed -$732K – 3912
2024
Q4 		$732K Sell
25,366
-23,900
-49% -$729K ﹤0.01% 2652
2024
Q3 		$1.17M Sell
49,266
-10,900
-18% -$242K ﹤0.01% 2345
2024
Q2 		$1.04M Buy
60,166
+13,300
+28% +$232K ﹤0.01% 2297
2024
Q1 		$1.05M Sell
46,866
-36,156
-44% -$752K ﹤0.01% 2460
2023
Q4 		$1.52M Buy
83,022
+45,251
+120% +$747K ﹤0.01% 2121
2023
Q3 		$656K Buy
37,771
+2,900
+8% +$50.4K ﹤0.01% 2581
2023
Q2 		$635K Buy
34,871
+2,271
+7% +$45.4K ﹤0.01% 2740
2023
Q1 		$559K Sell
32,600
-14,525
-31% -$235K ﹤0.01% 2826
2022
Q4 		$1.09M Sell
47,125
-27,442
-37% -$636K ﹤0.01% 2481
2022
Q3 		$1.66M Sell
74,567
-37,904
-34% -$903K ﹤0.01% 2150
2022
Q2 		$2.17M Buy
+112,471
New +$2.51M ﹤0.01% 2129

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Renaissance Technologies's LENZ Position: Q1 2025 in Review

Renaissance Technologies sold out of LENZ Therapeutics (LENZ) in Q1 2025, closing a stake of 25,366 shares — an estimated $732K sold.

Renaissance Technologies first reported a position in LENZ in Q2 2022 and held it in 11 quarters. The position peaked at $2.17M in Q2 2022. 105 funds tracked by Wall St. Rank hold LENZ as of Q1 2025.

  • Renaissance Technologies reported no remaining LENZ Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Renaissance Technologies sold 25,366 LENZ Therapeutics shares in Q1 2025, an estimated $732K.
  • Renaissance Technologies first reported a position in LENZ Therapeutics in Q2 2022 and held it in 11 quarters.
  • Renaissance Technologies's LENZ Therapeutics position peaked at $2.17M in Q2 2022.
  • 105 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2025.

Based on Renaissance Technologies's 13F filing for Q1 2025, filed 14 May 2025.